Immunome CSO receives stock options and RSUs grant
Higgins Jack reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Higgins Jack reported acquisition or exercise transactions in this Form 4 filing.
Immunome Inc. granted Chief Scientific Officer Jack Higgins 76,500 employee stock options to buy Common Stock at $22.01 per share, expiring in 2036, and 38,250 RSU-based Common Stock awards on 2026-07-23. Both the options and RSUs vest over time, subject to continuous service, and Higgins also reports indirect custodial holdings of 1,000 shares for each of three children, for which beneficial ownership is disclaimed.
Insider Trade Summary
Grant/Award: 114,750 shares
Grant/Award
5 txns
Insider
Higgins Jack
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F3 | 76,500 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 38,250 | $0.00 | $0.00 |
| holding | Common Stock F2 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
| holding | Common Stock F2 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 76,500 contracts (Direct);
Common Stock — 60,250 shares (Direct);
Common Stock — 1,000 shares (Indirect, As Custodian for Child 1);
Common Stock — 1,000 shares (Indirect, As Custodian for Child 2);
Common Stock — 1,000 shares (Indirect, As Custodian for Child 3)
Footnotes (3)
- F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
- F2. The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.
- F3. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Key Figures
Employee stock options granted: 76,500 shares
Option exercise price: $22.01 per share
Option expiration date: 2036-07-22
+4 more
7 metrics
Employee stock options granted
76,500 shares
Grant on 2026-07-23, employee stock options to buy Common Stock
Option exercise price
$22.01 per share
Exercise price for 76,500 employee stock options granted 2026-07-23
Option expiration date
2036-07-22
Expiration of the 76,500 employee stock options
RSUs granted
38,250 shares
Common Stock underlying RSUs granted 2026-07-23; 25% vests annually
Direct holdings after grant
60,250 shares
Total Common Stock/RSU direct holdings reported following 2026-07-23 RSU grant
Indirect custodial holdings per child
1,000 shares
Common Stock held as custodian for each of three children; beneficial ownership disclaimed
Initial option vesting tranche
25%
25% of option shares vest on July 23, 2027, with remaining vesting monthly thereafter
Key Terms
restricted stock units ("RSUs"), Uniform Transfer to Minors Act, beneficial ownership, continuous service
4 terms
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Uniform Transfer to Minors Act financial
"serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act."
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
continuous service financial
"subject to the Reporting Person's continuous service through each such vesting date."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunome (IMNM) grant to Chief Scientific Officer Jack Higgins?
Immunome granted Jack Higgins 76,500 employee stock options and 38,250 RSU-based Common Stock awards on 2026-07-23. The options have a $22.01 exercise price and expire in 2036, while the RSUs represent a contingent right to receive Common Stock upon settlement.
What are the vesting terms for Jack Higgins’ new RSUs at Immunome (IMNM)?
The 38,250 RSUs vest and settle into Common Stock over four years. 25% of the RSUs vest on each anniversary of the grant date, provided Higgins remains in continuous service through each vesting date.
How do Jack Higgins’ newly granted stock options at Immunome (IMNM) vest?
Of the 76,500 options, 25% vest on July 23, 2027. One-thirty-sixth of the remaining options then vests each month thereafter, conditioned on Higgins’ continuous service through each monthly vesting date.
What is the exercise price and expiration date of Jack Higgins’ Immunome (IMNM) stock options?
Higgins’ employee stock options cover 76,500 shares of Common Stock at an exercise price of $22.01 per share. These options are scheduled to expire on July 22, 2036, if not earlier exercised or forfeited under their terms.
What are Jack Higgins’ reported direct and indirect Common Stock holdings in Immunome (IMNM) after these awards?
Following the RSU grant, Higgins reports 60,250 shares of Common Stock/RSUs as directly held. He is also custodian for 1,000 shares in each of three child accounts, but disclaims beneficial ownership of those indirect custodial holdings.
Are Jack Higgins’ Immunome (IMNM) equity grants reported as made under a Rule 10b5-1 trading plan?
No. The Form 4’s Rule 10b5-1 checkbox is not marked as indicating that these transactions were effected pursuant to a Rule 10b5-1 trading plan, and no footnote states that they were plan-based.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates